口服抗肿瘤中成药对肝内胆管癌患者预后的影响  

Effect of Oral Antitumor Chinese Patent Medicines on the Prognosis of Patients with Intrahepatic Cholangiocarcinoma

作　　者：苗慧 孙华 万迁迁 时良慧 杨子玉 黄念 郭威 孙保木 万旭英 MIAO Hui;Sun Hua;WAN Qianqian;SHI Lianghui;YANG Ziyu;HUANG Nian;GUO Wei;SUN Baomu;WAN Xuying(The Third Affiliated Hospital of Naval Military Medical University,Shanghai 200438,China;Suzhou Hospital of Traditional Chinese Medicine Affiliated of Nanjing University of Traditional Chinese Medicine,Jiangsu Suzhou 2150000,China;Naval Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学第三附属医院中西医,上海200438 [2]南京中医药大学附属苏州市中医医院,江苏苏州215000 [3]海军军医大学军队卫生统计学教研室,上海200433

出　　处：《中医药临床杂志》2025年第3期541-547,共7页Clinical Journal of Traditional Chinese Medicine

基　　金：上海市卫健委临床研究专项(202340091);苏州市科技发展计划(SKJYD2021233)。

摘　　要：目的:探讨口服抗肿瘤中成药对肝内胆管癌患者预后的影响。方法:回顾性分析东方肝胆外科医院安亭院区收治的确诊为肝内胆管癌的患者198例,其中口服抗肿瘤中成药组67例,未经口服抗肿瘤中成药组131例。将两组患者进行倾向性评分匹配(1:1配对52对),比较2组患者的一般资料和预后,并采用COX比例风险回归模型分析影响肝内胆管癌患者预后的独立影响因素。结果:口服抗肿瘤中成药是影响肝内胆管癌患者总体生存的独立影响因素。无论是否行倾向性评分匹配,Kaplan-Mier生存分析均显示口服抗肿瘤中药组生存率及无进展生存率均高于未口服中药组。服药3~6月组、>6月组生存曲线均高于未口服抗肿瘤中成药组。口服抗肿瘤中成药组总体死亡风险低于未口服抗肿瘤中成药组;口服中药时间越长,死亡风险越低。结论:口服抗肿瘤中成药治疗肝内胆管癌可以改善患者的预后;口服中成药时间越长,死亡风险越低。Objective:To investigate the effect of oral anti-tumor Chinese patent medicine on the prognosis of pa-tients with intrahepatic cholangiocarcinoma.Methods:A retrospective analysis was performed on 198 patients diag-nosed with intrahepatic cholangiocarcinoma admitted to the Anting branch of our hospital,including 67 patients in the oral anti-tumor Chinese patent medicine group and 131 patients in the non-oral anti-tumor Chinese patent medicine group.The two groups were matched by propensity score(1:1 matching,52 pairs),and the general data and prognosis of the two groups were compared.The COX proportional hazard regression model was used to analyze the independent influencing factors affecting the prognosis of patients with intrahepatic cholangiocarcinoma.Results:Oral anti-tumor Chinese patent medicine is an independent influencing factor affecting the overall survival of patients with intrahepatic cholangiocarcinoma.Regardless of whether propensity score matching was performed,Kaplan-Mier survival analysis showed that the survival rate and progression-free survival rate of the oral anti-tumor Chinese patent medicine group were higher than those of the non-oral Chinese patent medicine group.The survival curves of the 3-6 month group and the>6 month group were higher than those of the non-oral anti-tumor Chinese patent medicine group.The overall mor-tality risk of the oral anti-tumor Chinese patent medicine group was lower than that of the non-oral anti-tumor Chinese patent medicine group;the longer the oral Chinese patent medicine was taken,the lower the mortality risk.Conclusion:Oral anti-tumor Chinese patent medicine can improve the prognosis of patients with intrahepatic cholangiocarcinoma;the longer the oral Chinese patent medicine was taken,the lower the mortality risk.

关 键 词：肝内胆管癌 中成药 抗肿瘤 预后 

分 类 号：R273[医药卫生—中西医结合]